The 36-month beta value for NAMS is at 0.16. Analysts have varying views on the stock, with 5 analysts rating it as a “buy,” 5 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for NAMS is 44.68M, and currently, shorts hold a 1.61% of that float. The average trading volume for NAMS on November 15, 2024 was 340.26K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
NAMS) stock’s latest price update
NewAmsterdam Pharma Company NV (NASDAQ: NAMS) has seen a rise in its stock price by 1.50 in relation to its previous close of 24.60. However, the company has experienced a 10.29% gain in its stock price over the last five trading sessions. globenewswire.com reported 2024-11-01 that NAARDEN, The Netherlands and MIAMI, Nov. 01, 2024 (GLOBE NEWSWIRE) — NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that the Compensation Committee of NewAmsterdam’s Board of Directors approved the grant of inducement share options covering an aggregate of 97,600 of NewAmsterdam’s ordinary shares to two non-executive new hires. The share options were granted as an inducement material to the employees’ acceptance of employment with NewAmsterdam pursuant to the NewAmsterdam Pharma Company N.V. 2024 Inducement Plan (the “2024 Inducement Plan”) and in accordance with Nasdaq Listing Rule 5635(c)(4).
NAMS’s Market Performance
NAMS’s stock has risen by 10.29% in the past week, with a monthly rise of 31.42% and a quarterly rise of 55.77%. The volatility ratio for the week is 4.19% while the volatility levels for the last 30 days are 5.67% for NewAmsterdam Pharma Company NV The simple moving average for the past 20 days is 21.80% for NAMS’s stock, with a 28.54% simple moving average for the past 200 days.
Analysts’ Opinion of NAMS
Scotiabank, on the other hand, stated in their research note that they expect to see NAMS reach a price target of $35. The rating they have provided for NAMS stocks is “Sector Outperform” according to the report published on March 14th, 2024.
Guggenheim gave a rating of “Buy” to NAMS, setting the target price at $30 in the report published on January 18th of the current year.
NAMS Trading at 36.04% from the 50-Day Moving Average
After a stumble in the market that brought NAMS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -5.24% of loss for the given period.
Volatility was left at 5.67%, however, over the last 30 days, the volatility rate increased by 4.19%, as shares surge +31.21% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +54.14% upper at present.
During the last 5 trading sessions, NAMS rose by +10.29%, which changed the moving average for the period of 200-days by +21.98% in comparison to the 20-day moving average, which settled at $20.50. In addition, NewAmsterdam Pharma Company NV saw 123.55% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at NAMS starting from NAP PoolCo B.V., who proposed sale 1,553,759 shares at the price of $24.98 back on Nov 13 ’24. After this action, NAP PoolCo B.V. now owns shares of NewAmsterdam Pharma Company NV, valued at $38,812,900 using the latest closing price.
Kooij Louise Frederika, the Chief Accounting Officer of NewAmsterdam Pharma Company NV, sale 45,000 shares at $15.72 during a trade that took place back on Oct 01 ’24, which means that Kooij Louise Frederika is holding 0 shares at $707,400 based on the most recent closing price.
Stock Fundamentals for NAMS
Current profitability levels for the company are sitting at:
- -4.96 for the present operating margin
- 1.0 for the gross margin
The net margin for NewAmsterdam Pharma Company NV stands at -5.35. The total capital return value is set at -0.43.
Currently, EBITDA for the company is -165.69 million with net debt to EBITDA at 2.57. When we switch over and look at the enterprise to sales, we see a ratio of 51.76. The liquidity ratio also appears to be rather interesting for investors as it stands at 10.61.
Conclusion
In conclusion, NewAmsterdam Pharma Company NV (NAMS) has had a better performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
